Filing Flows › Halozyme Therapeutics (HALO) › Revenues under collaborative agreements revenue
Halozyme Therapeutics (HALO) Revenues under collaborative agreements revenue by quarter
Halozyme Therapeutics' Revenues under collaborative agreements revenue was $14.6M in Q3 2026 (third quarter 2026), -66% from Q2 2026. Over the last 5 quarters it ranged from $14.6M (Q3 2026) to $43.7M (Q2 2026).
| Quarter | Revenues under collaborative agreements revenue | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | $14.6M | -66% | -39% |
| Q2 2026 | $43.7M | +82% | +13% |
| Q3 2025 | $24.0M | -38% | — |
| Q2 2025 | $38.6M | +107% | — |
| Q1 2025 | $18.6M | — | — |
Q3 2026 at a glance
Halozyme Therapeutics, Q3 2026: revenue $493M (+39% year over year), operating margin 59.8%, net earnings $247M, operating cash flow $258M. The chart follows the revenue to costs, profit and cash.
Questions
What is Halozyme Therapeutics' Revenues under collaborative agreements revenue?
Halozyme Therapeutics' Revenues under collaborative agreements revenue was $14.6M in Q3 2026 (third quarter 2026), -66% from Q2 2026.
How has Halozyme Therapeutics' Revenues under collaborative agreements revenue changed?
Over the last 5 quarters it ranged from $14.6M (Q3 2026) to $43.7M (Q2 2026).